Furthermore, based on the Breast Cancer Diagnosis and Treatment Guidelines published by the National Health Commission of China in 2022,19 we screened the CPADS drug database to investigate potential target drugs for treating high SULF1 expression among the current treatment regimens for advanced breast cancer patients. This evidence concerns the gene SULF1 and breast carcinoma.